		OF HEALTH AND HUM			
DISTRICT ADDRESS AND PHON	DNE NUMBER		DATE(S) OF INSPECTION	171	
Parsippany, N	Blvd., 3rd Floor NJ 07054		11/13/2017-11/30/20 FEINUMBER	L / *	
	900 Fax: (973) 331-4969		3013931875		
NAME AND TITLE OF INDIVIDUA	L TO WHOM REPORT ISSUED				
Michael Rutkowski, Vice President and General Manager					
FIRM NAME					
QuVa Pharma,					
Bloomsbury, N	J 08804-4047	4-4047 Outsourcing Facility			
This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.					
DURING AN INSPECTION OF YOUR FIRM WE OBSERVED: OBSERVATION 1					
Written procedures for sanitation are not followed.					
cleaning of the A (b Bulk, Lot log for ISO-7 cl	(b) (4) compound	for production act	vning/ante-rooms) should ivities". However, Hepa was not documented in t	rin 1unit/mL 3L	
	DN 2 action and control records ar master production or control				
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Tonia F Bernard, Inves Zakaria I Ganiyu, Inve		Tonia F Bernard Investigator Signed Dy. 2001637553 Date Signed: 11-30-2017 06:43	DATE ISSUED 11/30/2017	
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL	DBSERVATIONS	PAGE 1 OF 2 PAGES	

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION					
DISTRICT ADDRESS AND PHONE NUMBER 10 Waterview Blvd., 3rd Floor	DATE(S) OF INSPECTION 11/13/2017-11/30/2017*				
Parsippany, NJ 07054	FEINUMBER 3013931875				
(973)331-4900 Fax:(973)331-4969	5015551070				
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Michael Rutkowski, Vice President and General Manager					
FIRM NAME STREET ADDRESS					
QuVa Pharma, Inc. CITY, STATE, ZIP CODE, COUNTRY	519 State Route 173 TYPE ESTABLISHMENT INSPECTED				
Bloomsbury, NJ 08804-4047	Outsourcing Facility				
Specifically, the (b) (4) noted in step 8 of the approved batch record for Heparin lunit/mL 3L Bulk, Lot (b) (4), compounded on 11/06/17, states to '(b) (4), with (b) (4), However, there was no documentation in the batch record to justify that (b) (4), used for the (b) (4), not (b) (4), This lot was approved and released by Quality on 11/15/17 for further packaging into individually dosed syringes at your Sugar Land, TX facility. *DATES OF INSPECTION 11/13/2017(Mon), 11/14/2017(Tue), 11/15/2017(Wed), 11/16/2017(Thu), 11/17/2017(Fri), 11/21/2017(Tue), 11/30/2017(Thu) X Example 2 and the package at the					
SEE REVERSE OF THIS PAGE Zakaria I Ganiyu, Investiga					
FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE I	NSPECTIONAL OBSERVATIONS PAGE 2 OF 2 PAGES				